高级检索
    申恒, 魏辉, 谈家齐. CPX-351对比“7+3”化疗在初诊高危或继发性急性髓系白血病老年患者中的5年随访结果[J]. 循证医学, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
    引用本文: 申恒, 魏辉, 谈家齐. CPX-351对比“7+3”化疗在初诊高危或继发性急性髓系白血病老年患者中的5年随访结果[J]. 循证医学, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
    shu
    SHEN Heng, WEI Hui, TAN Jia-qi. 5-Year Follow-Up Results of CPX-351 Versus 7+3 Chemotherapy in Older Adults With Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
    Citation: SHEN Heng, WEI Hui, TAN Jia-qi. 5-Year Follow-Up Results of CPX-351 Versus 7+3 Chemotherapy in Older Adults With Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
    shu

    CPX-351对比“7+3”化疗在初诊高危或继发性急性髓系白血病老年患者中的5年随访结果

    5-Year Follow-Up Results of CPX-351 Versus 7+3 Chemotherapy in Older Adults With Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia

      摘要
      • HTML全文
      • 参考文献(6)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回